British multinational pharmaceutical and biotech company GSK announced a three-year agreement with an initial payment of $70 million to expand access to Tempus’ AI-powered data library, including anonymized patient data.
GSK says the collaboration will enable it to leverage the US-based company’s library to accelerate drug discovery in oncology, improve clinical trial design, identify drug targets and enroll in trials to speed up.
After three years, GSK has the option to extend the agreement for a further two years.
The partnership builds on GSK and Tempus’ existing partnership focused on enrolling patients with specific cancer types in clinical trials, giving GSK specific access to Tempus’ anonymized patient data.
The companies are currently collaborating on an open-label Phase II study, using a data-driven approach designed to accelerate study timelines.
“This collaboration will provide GSK with unique insights to discover better drugs and transform drug discovery. Tempus complements the work our team is already doing at the intersection of genomics and machine learning in both early discovery and clinical trials,” Tony Wood, Chief Scientific Officer at GSK, said in a statement.
THE BIGGER TREND
GSK has partnered with numerous companies over the past year to strengthen its clinical research functions.
In April of this year, GSK announced a multi-year drug discovery collaboration with an AI-enabled pathology company PathAI advances clinical trials and drug development in oncology and for non-alcoholic steatohepatitis (NASH).
Earlier this year, GSK announced it has extended its drug discovery partnership with the consumer genetics company 23andMe until July 2023. That partnership began in 2018 when GSK provided $300 million to the now publicly traded company.
Last year, GSK expanded its partnership with: Viome Life Sciences, a maker of home tests for gut and immune health. The alliance will allow GSK to study the link between the gut microbiome and some chronic diseases, such as autoimmune diseases.